Bio-Path (BPTH) Competitors $0.17 0.00 (-2.29%) As of 07/3/2025 12:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. FRTX, ENSC, ALBT, APM, ATNF, CNSP, THAR, MYNZ, SNOA, and MTNBShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Fresh Tracks Therapeutics (FRTX), Ensysce Biosciences (ENSC), Avalon GloboCare (ALBT), Aptorum Group (APM), 180 Life Sciences (ATNF), CNS Pharmaceuticals (CNSP), Tharimmune (THAR), Mainz Biomed (MYNZ), Sonoma Pharmaceuticals (SNOA), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors Fresh Tracks Therapeutics Ensysce Biosciences Avalon GloboCare Aptorum Group 180 Life Sciences CNS Pharmaceuticals Tharimmune Mainz Biomed Sonoma Pharmaceuticals Matinas Biopharma Bio-Path (NASDAQ:BPTH) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk & volatility, BPTH or FRTX? Bio-Path has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Does the media favor BPTH or FRTX? In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Fresh Tracks Therapeutics'average media sentiment score. Company Overall Sentiment Bio-Path Neutral Fresh Tracks Therapeutics Neutral Is BPTH or FRTX more profitable? Fresh Tracks Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Fresh Tracks Therapeutics N/A N/A N/A Do institutionals and insiders believe in BPTH or FRTX? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, BPTH or FRTX? Fresh Tracks Therapeutics has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/AFresh Tracks Therapeutics$10.06M0.56-$5.69M-$1.41-0.66 Do analysts recommend BPTH or FRTX? Bio-Path presently has a consensus target price of $20.00, indicating a potential upside of 11,609.60%. Given Bio-Path's stronger consensus rating and higher probable upside, analysts plainly believe Bio-Path is more favorable than Fresh Tracks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Fresh Tracks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryFresh Tracks Therapeutics beats Bio-Path on 6 of the 10 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42M$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E RatioN/A1.1327.5220.22Price / SalesN/A226.97421.02118.64Price / CashN/A23.4436.8958.07Price / Book0.246.298.045.67Net Income-$16.08M-$27.73M$3.18B$249.13M7 Day Performance-2.90%1.82%2.90%3.28%1 Month Performance-8.66%9.90%3.70%5.55%1 Year Performance-90.01%10.79%36.15%21.12% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path2.5844 of 5 stars$0.17-2.3%$20.00+11,609.6%-90.4%$1.42MN/A0.0010Gap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+0.6%$5.59M$10.06M-0.6620ENSCEnsysce BiosciencesN/A$2.23-0.4%N/A-65.9%$5.31M$5.21M-0.3410ALBTAvalon GloboCare1.5306 of 5 stars$2.78flatN/A-64.4%$5.27M$1.33M-0.145News CoveragePositive NewsAPMAptorum Group0.6316 of 5 stars$0.91-6.3%N/A-75.7%$5.19M$430K0.0030Gap UpATNF180 Life Sciences0.5931 of 5 stars$0.93+11.8%N/A-44.5%$5.04MN/A0.007Gap UpCNSPCNS Pharmaceuticals1.6972 of 5 stars$0.83-6.1%$25.00+2,930.3%-98.7%$4.80MN/A0.005News CoverageTHARTharimmune3.3738 of 5 stars$1.94+7.6%$17.00+776.2%-44.7%$4.80MN/A-0.252Positive NewsMYNZMainz Biomed2.7735 of 5 stars$1.41+2.2%$14.00+892.9%-89.3%$4.75M$890K-0.0230Gap UpSNOASonoma PharmaceuticalsN/A$2.85-0.7%N/A+969.6%$4.71M$14.29M-0.92180Positive NewsMTNBMatinas BiopharmaN/A$0.89-3.3%N/AN/A$4.53MN/A-0.1830 Related Companies and Tools Related Companies FRTX Alternatives ENSC Alternatives ALBT Alternatives APM Alternatives ATNF Alternatives CNSP Alternatives THAR Alternatives MYNZ Alternatives SNOA Alternatives MTNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
